Financial Reporting

IFRS 2 vs. ASC 718: How Share-Based Payment Accounting Differs for Global Startups

IFRS 2 and ASC 718 both expense stock options at fair value, but they diverge on forfeitures, graded vesting, and deferred tax. Here is where and why.

By 409.AI Team - 2026-07-22

# IFRS 2 vs. ASC 718: How Share-Based Payment Accounting Differs for Global Startups

The first time a US founder runs into IFRS 2 is usually a surprise. You've been expensing your option grants under US GAAP, your auditors are happy, and then a European fund leads your Series B and asks for financials under International Financial Reporting Standards. Or you spin up a UK subsidiary to hire engineers in London, and its statutory accounts have to follow IFRS. Suddenly the same stock options you've already booked need to be measured again under a different rulebook, and the numbers don't match.

They're supposed to be close. IFRS 2 and ASC 718 were built to answer the same question: what does it cost a company to pay people in equity? But the two standards make different choices in a handful of places, and those choices change the timing and size of your compensation expense. If you report under both, or you're headed toward an IPO or acquisition where a buyer reports under IFRS, it's worth knowing exactly where they part ways.

Two standards, one idea

Both standards start from the same premise. When you grant someone equity for their work, that's an expense, and it should hit your income statement at the fair value of what you gave up. IFRS 2 *Share-based Payment* was issued by the IASB in February 2004 and took effect for periods beginning on or after 1 January 2005. Its US counterpart, ASC 718 (which grew out of the old FAS 123R), lands in the same place: measure the award at fair value, then spread that cost over the period the employee has to work to earn it.

If you've read our [guide to ASC 718 for startups](https://409.ai/articles/asc-718-stock-based-compensation-startup-guide), the mechanics will feel familiar. Grant an option, estimate its fair value, recognize the expense as it vests. IFRS 2 does the same at that level. The differences live in the details, and the details are where global finance teams lose time.

What IFRS 2 covers

IFRS 2 splits share-based payments into three buckets, and knowing which one you're in decides how you account for it.

Equity-settled awards are the common case: you give employees options or shares, and you settle in your own stock. You measure these at grant-date fair value and never remeasure them, no matter what happens to your share price afterward.

Cash-settled awards, like stock appreciation rights paid in cash or phantom shares, create a liability instead. Because you'll eventually pay cash tied to your share value, you remeasure the award at fair value at every reporting date until it settles, running each change through profit or loss.

Awards with a choice of settlement, where either the company or the employee can pick cash or shares, get split into liability and equity components depending on who holds the choice.

That first remeasurement rule is the one people forget. A cash-settled SAR that looked cheap at grant can balloon if your valuation climbs, because you keep marking it to fair value every quarter.

Measuring the expense when there's no market price

For a public company, measuring an option is mostly a modeling exercise. For a private startup, you first have to answer a harder question: what's the fair value of the underlying share? There's no ticker to look at.

IFRS 2 tells you to use an observable market price if one exists, and if it doesn't, to apply an option-pricing model such as Black-Scholes, a binomial lattice, or a Monte Carlo simulation. Every one of those models needs a current share price as an input, and that input has to be defensible. This is the same underlying valuation problem that drives a [409A valuation](https://409.ai/articles/what-is-a-409a-valuation-a-comprehensive-guide) in the US, and the same reason the [income approach](https://409.ai/articles/income-approach-409a-valuation) and market approach show up in both worlds. The label on the report changes with the framework; the discipline behind the number doesn't.

Here's a simple version. Say you grant 100,000 options with a Black-Scholes fair value of $4.00 each. Your total grant-date cost is $400,000. Under IFRS 2, that $400,000 is fixed at grant for an equity-settled award. What moves between the two standards isn't that total. It's how the $400,000 gets spread across the years, whether you adjust it for people who quit, and how the tax side gets recorded.

Where IFRS 2 and ASC 718 diverge

Forfeitures

Not everyone stays to vest. Under IFRS 2, you have to estimate how many awards will be forfeited and build that estimate into your expense from day one, truing it up as real attrition data comes in. ASC 718 gives US companies a choice: estimate forfeitures the same way, or (following ASU 2016-09) simply account for them as they actually happen. A startup with high early churn that elects the "as-they-occur" method under US GAAP will book a different expense pattern than the estimate-based number IFRS 2 forces. Same grant, two expense curves.

Graded vesting

This one catches almost every US team. Most options vest in tranches, say 25% a year over four years. Under ASC 718, if the only condition is continued service, you're allowed to recognize the whole cost on a straight-line basis. IFRS 2 doesn't let you. It treats each vesting tranche as a separate award and recognizes each one over its own vesting period, which front-loads the expense.

Take that $400,000 grant vesting 25% each year. Straight-line, ASC 718 gives you $100,000 of expense in each of the four years. IFRS 2 splits it into four tranches: the first vests in one year and is expensed entirely in year one, the second is spread over two years, the third over three, the fourth over four. Add up year one and you get roughly $208,000 of expense, more than double the straight-line figure. By year four you're recognizing only about $25,000. The lifetime cost is identical. The shape is completely different, and for a company watching its operating loss, that shape matters.

Deferred tax

The tax accounting splits too, and this is the subtle one. ASC 718 builds your deferred tax asset off the book compensation cost you've recognized. IFRS 2 instead bases it on the estimated future tax deduction, which for many options means the intrinsic value at each reporting date, remeasured as your share price moves. The practical effect is that your IFRS deferred tax asset swings with your valuation while your US GAAP one tracks a steadier book number. For a startup whose value is climbing round over round, the two can drift a long way apart. The tax treatment employees see also depends on the option type, which we cover in [ISO vs. NSO](https://409.ai/articles/iso-vs-nso-how-stock-options-are-taxed); the corporate deferred tax mechanics here are a separate layer on top of that.

No small-company shortcuts

ASC 718 hands private US companies several practical expedients, including simplified ways to estimate expected term, permission to fall back on an industry volatility benchmark when your own history is thin, and a practical expedient for determining the current price of the underlying share. IFRS 2 offers no equivalent carve-outs for private or smaller entities. Whatever rigor a public issuer applies, a pre-seed startup reporting under IFRS applies too. That raises the bar on your inputs, and it's one more reason the underlying valuation has to hold up.

The UK and cross-border angle

If your reason for touching IFRS 2 is a UK or European entity, the standard sits alongside a separate tax question. UK employee share schemes like EMI and CSOP have their own HMRC valuation rules, which we walk through in our piece on [EMI share options in 2026](https://409.ai/articles/emi-share-options-2026-uk-rules-hmrc-valuation). The HMRC agreed value governs the tax treatment of the option for the employee. IFRS 2 governs how the company reports the cost in its financial statements. They're different exercises answering different questions, and a UK subsidiary of a US startup can easily need both, plus the US GAAP number for the consolidated parent. Three valuations, one option pool.

What it means for your reporting

The headline is that IFRS 2 and ASC 718 agree on the concept and disagree on the mechanics, and the disagreements are big enough to change your reported loss, your deferred tax, and the story your financials tell an investor. If you only report under one framework today but expect a cross-border round, an overseas parent, or an IPO on a market that uses IFRS, it pays to model both early rather than discover the gap during diligence.

Underneath every one of these differences sits the same requirement: a defensible fair value for your shares and your options. Whether you're expensing under ASC 718, reporting a subsidiary under IFRS 2, or doing both, the model is only as good as the valuation feeding it, and that valuation has to be current. Most startups refresh it on the [same cadence they use for 409A](https://409.ai/articles/409a-valuation-frequency-how-often-should-you-get-one), at least annually and after any material event. Get the underlying number right and defensible, and the framework you report it under becomes a mechanical choice rather than a fire drill. 409.ai produces expert-reviewed [IFRS 2 valuations](https://409.ai/products/ifrs-2) for exactly this situation, built on the same valuation work that supports a US 409A.

If there's one thing to carry out of this: don't assume your US GAAP stock-comp expense transfers cleanly to IFRS. The vesting curve alone can nearly double your first-year expense. Model the IFRS 2 number before someone else does it for you.